“Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial”. SKIN The Journal of Cutaneous Medicine 3 (November 9, 2019): S17. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/744.